ABSTRACT Several studies reported on the humoral response in subjects having received the BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months post-vaccination are currently lacking and are important to drive the future vaccination strategy. The CRO-VAX HCP study is an ongoing multicentre, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals who had received two doses of the BNT162b2 mRNA COVID-19 vaccine. Two hundred individuals underwent a blood drawn within 2 days before the first vaccine dose. One-hundred and forty-two persons (71%) were categorized as seronegative at baseline while 58 (29%) were seropositive. Samples were then collected after 14, 28, 42, 56, and 90 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points. Using a one-compartment kinetics model, the time to maximum concentration was estimated at 36 ± 3 days after the first dose and the estimated half-life of antibodies was 55 days (95% CI: 37–107 days) in seronegative participants. In seropositive participants, the time to maximum concentration was estimated at 24 ± 4 days and the estimated half-life was 80 days (95% CI: 46–303 days). The antibody response was higher in seropositive compared to seronegative participants. In both seropositive and seronegative subjects, a significant antibody decline was observed at 3 months compared to the peak response. Nevertheless, the humoral response remained robust in all participants.
【저자키워드】 COVID-19, SARS-CoV-2, mRNA vaccine, Antibody Response, BNT162b2, 【초록키워드】 COVID-19 vaccine, antibody, healthcare professionals, Antibody Response, Spike protein, Receptor binding domain, vaccine dose, BNT162b2, Kinetics, Humoral response, nucleocapsid, multicentre, seropositive, seronegative, Blood, BNT162b2 mRNA COVID-19 vaccine, BNT162b2 mRNA, Healthcare professional, Concentration, S1 subunit, dose, Vaccination strategy, humoral, Participants, 95% CI, subject, All participants, seronegative participants, different time points, first dose, individual, maximum concentration, seropositive participants, SARS-CoV-2 nucleocapsid, hcp, robust, the S1 subunit, collected, Sample, reported, remained, subjects, the spike protein, the antibody response, were measured, baseline, kinetics of antibody, the SARS-CoV-2, 【제목키워드】 titre,